Online citations, reference lists, and bibliographies.
← Back to Search

Trough Levels And Concentration Time Curves Of Cyclosporine In Patients Undergoing Renal Transplantation

F. Frey, F. Horber, B. Frey
Published 1988 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
We determined the AUC of cyclosporine (24 hours) nonspecifically by RIA and specifically by HPLC after an oral and an intravenous dose of cyclosporine in 58 patients undergoing renal transplantation. The RIA/HPLC concentration ratio of cyclosporine changed continuously during the first 12 hours after administration. The ratio was higher after oral than after intravenous administration and varied from patient to patient. The predictive value of trough levels for the corresponding AUCs was better when trough levels were assessed 24 than 12 hours after administration. Trough levels assessed by RIA poorly predicted AUCs measured specifically by HPLC. Therefore if, in the future, therapeutic cyclosporine monitoring has to be improved, trough levels should be assessed 24 hours after the last dose by means of a specific HPLC method.
This paper references
10.1002/JPS.2600680845
Noncompartmental determination of the steady-state volume of distribution.
L. Benet (1979)
10.1080/01971528108062989
A radioimmunoassay to measure cyclosporin A in plasma and serum samples.
P. Donatsch (1981)
Methods to measure cyclosporine levels - high pressure liquid chromatography , radioimmunoassay and correlation
WT Robinson (1983)
High - performance liquid chromatographic determination of cyclosporine A in human plasma and urine
W Niederberger (1980)
10.1097/00007890-198511000-00001
INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS
B. Kahan (1985)
Liquid - chromatographic determination of cyclosporine A in blood and plasma
RJ Sawchuck (1981)
10.1210/JCEM-60-2-361
The effect of altered prednisolone kinetics in patients with the nephrotic syndrome and in women taking oral contraceptive steroids on human mixed lymphocyte cultures.
B. Frey (1985)
Suppressive effects of cyclosporine A on the induction of alloreactivity in vitro and in vivo
BS Wang (1981)
Metabolism of cyclosporine.
G. Maurer (1985)
Nephrotoxic and immunosuppressive potentials of cyclosporine metabolites in rats.
B. Ryffel (1986)
10.1007/BF01962250
Cyclosporin A: correlation between HPLC and RIA serum levels
E. Abisch (2005)
Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR.
A. Hess (1980)
10.1093/clinchem/33.7.1269
Critical issues in cyclosporine monitoring: report of the Task Force on Cyclosporine Monitoring.
L. M. Sahw (1987)
10.1038/clpt.1983.226
Intravenous cyclosporine kinetics in renal failure
F. Follath (1983)
Distribution and binding of cyclosporine in blood and tissues
W Niederberger (1982)
The effect of cyclosporin on T - lymphocyte subpopulations
AD Hess
Effects of cyclosporine A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells
AD Hess (1982)
10.1097/00007890-198604000-00009
DEMOGRAPHIC FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY
B. Kahan (1986)
Clin - ical pharmacokinetics of cyclosporine
RJ Ptachcinski (1986)
10.1097/00007890-198603000-00021
CYCLOSPORINE METABOLISM AND PHARMACOKINETICS FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION IN THE DOG1
B. Gridelli (1986)
Liquid chromatographic analysis of cyclosporine utilizing a microbore column and reduced specimen requirement
T Annesley (1986)
10.1111/j.2042-7158.1982.tb06206.x
Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood
M. Lemaire (1982)
10.1038/clpt.1985.174
Cyclosporine kinetics in renal transplantation
R. Ptachcinski (1985)
In vitro stability and storage of cyclosporine in human serum and plasma
J Smith (1983)
Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function.
B. Frey (1984)
pharmacokinetic and pharmacodynamic parameters. Transplantation
RJ Sawchuck (1981)
10.1016/0006-291X(85)91230-6
An acid metabolite of cyclosporine.
N. Hartman (1985)
10.1002/JHRC.1240050806
Determination of cyclosporin A in blood and plasma by column switching‐HPLC after rapid sample preparation
K. Nussbaumer (1982)



This paper is referenced by
10.1007/BF00315232
Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis
J. Tredger (2004)
10.1002/j.1552-4604.1989.tb03324.x
Influence of Demographic Factors on Cyclosporine Pharmacokinetics in Adult Uremic Patients
J. Grevel (1989)
10.1038/KI.1991.131
Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients.
F. Frey (1991)
10.1002/lt.20609
Cyclosporine exposure and calcineurin phosphatase activity in living‐donor liver transplant patients: Twice daily vs. once daily dosing
M. Fukudo (2006)
10.1111/j.1442-2042.1995.tb00444.x
INTRA‐ AND INTERINDIVIDUAL VARIATION IN THE PHARMACOKINETICS OF TACROLIMUS (FK506) IN KIDNEY TRANSPLANT RECIPIENTS—IMPORTANCE OF TROUGH LEVEL AS A PRACTICAL INDICATOR
H. Ihara (1995)
10.1097/00007691-200208000-00003
Comparison of Trough, 2-Hour, and Limited AUC Blood Sampling for Monitoring Cyclosporin (Neoral®) at Day 7 Post–Renal Transplantation and Incidence of Rejection in the First Month
R. Morris (2002)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.2165/00003088-199223030-00002
A Review of Assay Methods for Cyclosporin
K. Kivistö (1992)
10.1002/j.1552-4604.1996.tb04221.x
Pharmacokinetics of Cyclosporine after Renal Transplant in Children
M. Mochon (1996)
10.1248/BPB1978.13.20
A model to account for the blood-to-plasma distribution of cyclosporin A in human blood.
N. Shibata (1990)
10.1111/j.1432-2277.1996.tb00912.x
Long‐term cyclosporin A pharmacokinetic profiles in pediatric renal transplant recipients
A. Kelles (1996)
10.1111/J.1365-2125.1992.TB04108.X
Enhancement of the oral absorption of cyclosporin in man.
J. Drewe (1992)
10.2165/00003088-198916030-00002
Clinical Pharmacokinetics in Organ Transplant Patients
R. Venkataramanan (1989)
10.1002/j.1875-9114.1991.tb04290.x
Therapeutic Drug Monitoring of Cyclosporine‐Lipoprotein Levels
J. C. Yau (1991)
10.2165/00044011-199713010-00004
A Pharmacokinetic Study of Cyclosporin (Sandimmune®)
D. Primmett (1997)
10.1161/01.ATV.14.5.780
Cotranslational inhibition of apoB-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2.
A. Kaptein (1994)
10.1111/J.1365-2125.1995.TB04425.X
Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis.
B. E. van den Borne (1995)
10.1111/J.1365-2125.1990.TB03677.X
The effect of food and bile acid administration on the relative bioavailability of cyclosporin.
A. Lindholm (1990)
10.1007/978-1-60761-642-9_3
Immunosuppressive Therapy in Kidney and Pancreas Transplantation
G. Thomas (2011)
10.1007/BF00335553
Long-term cyclosporin A pharmacokinetic profiles in pediatric renal transplant recipients
A. Kelles (1996)
10.1002/HEP.1840090416
Impaired liver function in stable renal allograft recipients
F. Frey (1989)
10.1081/RRS-100107429
LIPID-BASED FORMULATIONS FOR ORAL ADMINISTRATION: OPPORTUNITIES FOR BIOAVAILABILITY ENHANCEMENT AND LIPOPROTEIN TARGETING OF LIPOPHILIC DRUGS
C. J. Porter (2001)
10.1007/S001470050101
Impact of early cyclosporin average blood concentration on early kidney transplant failure
M. Ferda Senel (1998)
10.2165/00003088-199324060-00004
Cyclosporin Clinical Pharmacokinetics
A. Fahr (1993)
10.1111/j.1432-2277.1998.tb00955.x
Impact of early cyclosporin average blood concentration on early kidney transplant failure
M. Ferda Senel (1998)
10.2165/00003088-200241010-00005
Population Pharmacokinetic Model to Predict Steady-State Exposure to Once-Daily Cyclosporin Microemulsion in Renal Transplant Recipients
F. Schaedeli (2002)
10.2165/00003088-199732060-00004
Cyclosporin Pharmacokinetics in Paediatric Transplant Recipients
G. J. Cooney (1997)
10.1111/j.1432-2277.1989.tb01863.x
An explanation of the noncorrespondence between assessment methods of cyclosporin
G. M. Randleff-Rasmussen (1989)
10.1097/00075198-200108000-00006
Current immunosuppressant regimens: considerations for critical care
B. Kahan (2001)
10.1517/17425247.2012.694865
Microemulsions for oral administration and their therapeutic applications
S. Gibaud (2012)
10.1007/BF00271369
On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation
S. Ohlman (2004)
10.1007/BF02414531
An explanation of the noncorrespondence between assessment methods of cyclosporin
G. M. Randleff-Rasmussen (1989)
See more
Semantic Scholar Logo Some data provided by SemanticScholar